Role of AcrR and RamA in Fluoroquinolone Resistance in Clinical Klebsiella pneumoniae Isolates from Singapore

ABSTRACT The MICs of ciprofloxacin for 33 clinical isolates of K. pneumoniae resistant to extended-spectrum cephalosporins from three hospitals in Singapore ranged from 0.25 to >128 μg/ml. Nineteen of the isolates were fluoroquinolone resistant according to the NCCLS guidelines. Strains for which the ciprofloxacin MIC was ≥0.5 μg/ml harbored a mutation in DNA gyrase A (Ser83→Tyr, Leu, or IIe), and some had a secondary Asp87→Asn mutation. Isolates for which the MIC was 16 μg/ml possessed an additional alteration in ParC (Ser80→IIe, Trp, or Arg). Tolerance of the organic solvent cyclohexane was observed in 10 of the 19 fluoroquinolone-resistant strains; 3 of these were also pentane tolerant. Five of the 10 organic solvent-tolerant isolates overexpressed AcrA and also showed deletions within the acrR gene. Complementation of the mutated acrR gene with the wild-type gene decreased AcrA levels and produced a two- to fourfold reduction in the fluoroquinolone MICs. None of the organic solvent-tolerant clinical isolates overexpressed another efflux-related gene, acrE. While marA and soxS were not overexpressed, another marA homologue, ramA, was overexpressed in 3 of 10 organic solvent-tolerant isolates. These findings indicate that multiple target and nontarget gene changes contribute to fluoroquinolone resistance in K. pneumoniae. Besides AcrR mutations, ramA overexpression (but not marA or soxS overexpression) was related to increased AcrAB efflux pump expression in this collection of isolates.

[1]  P. Nordmann,et al.  Emergence in Klebsiella pneumoniae of a Chromosome-Encoded SHV β-Lactamase That Compromises the Efficacy of Imipenem , 2003, Antimicrobial Agents and Chemotherapy.

[2]  G. Cornaglia,et al.  AcrAB Efflux System: Expression and Contribution to Fluoroquinolone Resistance in Klebsiella spp , 2002, Antimicrobial Agents and Chemotherapy.

[3]  L. Martínez-Martínez,et al.  Energy-Dependent Accumulation of Norfloxacin and Porin Expression in Clinical Isolates of Klebsiella pneumoniae and Relationship to Extended-Spectrum β-Lactamase Production , 2002, Antimicrobial Agents and Chemotherapy.

[4]  F. Notka,et al.  Increase in MICs of ciprofloxacin in vivo in two closely related clinical isolates of Enterobacter cloacae. , 2002, The Journal of antimicrobial chemotherapy.

[5]  S. Levy,et al.  Genetic Characterization of Highly Fluoroquinolone-Resistant Clinical Escherichia coli Strains from China: Role ofacrR Mutations , 2001, Antimicrobial Agents and Chemotherapy.

[6]  M. Webber,et al.  Absence of Mutations in marRAB or soxRS inacrB-Overexpressing Fluoroquinolone-Resistant Clinical and Veterinary Isolates of Escherichia coli , 2001, Antimicrobial Agents and Chemotherapy.

[7]  W. Kern,et al.  Enhanced Expression of the Multidrug Efflux Pumps AcrAB and AcrEF Associated with Insertion Element Transposition in Escherichia coli Mutants Selected with a Fluoroquinolone , 2001, Antimicrobial Agents and Chemotherapy.

[8]  S. Levy,et al.  A soxRS-Constitutive Mutation Contributing to Antibiotic Resistance in a Clinical Isolate of Salmonella enterica (Serovar Typhimurium) , 2001, Antimicrobial Agents and Chemotherapy.

[9]  L. Piddock,et al.  Evidence for an Efflux Pump Mediating Multiple Antibiotic Resistance in Salmonella enterica Serovar Typhimurium , 2000, Antimicrobial Agents and Chemotherapy.

[10]  J. Pagés,et al.  Membrane permeability modifications are involved in antibiotic resistance in Klebsiella pneumoniae. , 2000, Biochemical and biophysical research communications.

[11]  S. Levy,et al.  Non-Target Gene Mutations in the Development of Fluoroquinolone Resistance in Escherichia coli , 2000, Antimicrobial Agents and Chemotherapy.

[12]  H. Goossens,et al.  Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  S. Levy,et al.  Ineffectiveness of Topoisomerase Mutations in Mediating Clinically Significant Fluoroquinolone Resistance inEscherichia coli in the Absence of the AcrAB Efflux Pump , 2000, Antimicrobial Agents and Chemotherapy.

[14]  K. Köhrer,et al.  Comparative In Vitro Activities of Ciprofloxacin, Clinafloxacin, Gatifloxacin, Levofloxacin, Moxifloxacin, and Trovafloxacin againstKlebsiella pneumoniae, Klebsiella oxytoca,Enterobacter cloacae, and Enterobacter aerogenes Clinical Isolates with Alterations in GyrA and ParC Proteins , 1999, Antimicrobial Agents and Chemotherapy.

[15]  S. Levy,et al.  Alteration of the Repressor Activity of MarR, the Negative Regulator of the Escherichia coli marRAB Locus, by Multiple Chemicals In Vitro , 1999, Journal of bacteriology.

[16]  G. Jacoby,et al.  Roles of β-Lactamases and Porins in Activities of Carbapenems and Cephalosporins against Klebsiella pneumoniae , 1999, Antimicrobial Agents and Chemotherapy.

[17]  L. Martínez-Martínez,et al.  Porin expression in clinical isolates of Klebsiella pneumoniae. , 1999, Microbiology.

[18]  Jin-Hong Yoo,et al.  Molecular analysis of fluoroquinolone-resistance in Escherichia coli on the aspect of gyrase and multiple antibiotic resistance (mar) genes. , 1998, Yonsei medical journal.

[19]  R. Podschun,et al.  Klebsiella spp. as Nosocomial Pathogens: Epidemiology, Taxonomy, Typing Methods, and Pathogenicity Factors , 1998, Clinical Microbiology Reviews.

[20]  L. Martínez-Martínez,et al.  Energy-Dependent Accumulation of Fluoroquinolones in Quinolone-Resistant Klebsiella pneumoniae Strains , 1998, Antimicrobial Agents and Chemotherapy.

[21]  M. Yasuda,et al.  In vivo selection of Klebsiella pneumoniae strains with enhanced quinolone resistance during fluoroquinolone treatment of urinary tract infections , 1997, Antimicrobial agents and chemotherapy.

[22]  M. Yasuda,et al.  Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV in quinolone-resistant clinical isolates of Klebsiella pneumoniae , 1997, Antimicrobial agents and chemotherapy.

[23]  S. Levy,et al.  Identification for mar mutants among quinolone-resistant clinical isolates of Escherichia coli , 1996, Antimicrobial agents and chemotherapy.

[24]  G. Jacoby,et al.  In vivo selection of porin-deficient mutants of Klebsiella pneumoniae with increased resistance to cefoxitin and expanded-spectrum-cephalosporins , 1996, Antimicrobial agents and chemotherapy.

[25]  H. Nikaido,et al.  AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic-resistance (Mar) mutants , 1996, Journal of bacteriology.

[26]  A. M. George,et al.  Multidrug resistance in Klebsiella pneumoniae: a novel gene, ramA, confers a multidrug resistance phenotype in Escherichia coli. , 1995, Microbiology.

[27]  J. Wu,et al.  Two-stage induction of the soxRS (superoxide response) regulon of Escherichia coli , 1992, Journal of bacteriology.

[28]  Y. Arakawa,et al.  Increased resistance to multiple drugs by introduction of the Enterobacter cloacae romA gene into OmpF porin-deficient mutants of Escherichia coli K-12 , 1991, Antimicrobial Agents and Chemotherapy.

[29]  P. Monach,et al.  Activation of oxidative stress genes by mutations at the soxQ/cfxB/marA locus of Escherichia coli , 1991, Journal of bacteriology.

[30]  B Demple,et al.  Positive control of a global antioxidant defense regulon activated by superoxide-generating agents in Escherichia coli. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[31]  A. M. George,et al.  Amplifiable resistance to tetracycline, chloramphenicol, and other antibiotics in Escherichia coli: involvement of a non-plasmid-determined efflux of tetracycline , 1983, Journal of bacteriology.

[32]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[33]  P. Nordmann,et al.  Emergence in Klebsiella pneumoniae of a Chromosome-Encoded SHV (cid:2) -Lactamase That Compromises the Efficacy of Imipenem , 2003 .

[34]  F. Notka,et al.  A C-terminal 18 amino acid deletion in MarR in a clinical isolate of Escherichia coli reduces MarR binding properties and increases the MIC of ciprofloxacin. , 2002, The Journal of antimicrobial chemotherapy.

[35]  S. Brisse,et al.  Epidemiology of Quinolone Resistance of Klebsiella pneumoniae and Klebsiella oxytoca in Europe , 2000, European Journal of Clinical Microbiology and Infectious Diseases.

[36]  D. Greenwood,et al.  A GUIDE TO SENSITIVITY TESTING , 1991 .

[37]  D. Wilbur,et al.  An evaluation of the susceptibility patterns of gram-negative organisms isolated in cancer centres with aminoglycoside usage. , 1991, The Journal of antimicrobial chemotherapy.

[38]  R. Cox.  Amantadine prophylaxis for health care workers: unanswered questions. , 1991, The Journal of antimicrobial chemotherapy.